Freya Biosciences Announces $38 Million Funding in One of the Largest Series A Raises to Advance Women’s Reproductive Immunotherapies
Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies.
- Freya Biosciences, a trans-Atlantic biotech company specializing in women's health, announced today a $38 million Series A financing – one of the largest raises to advance women’s reproductive immunotherapies.
- “We are very excited to announce Freya’s Series A fundraise, with the support of this dedicated team of investors,” said Colleen Acosta, CEO of Freya Biosciences.
- “Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to its burden on human health.
- The funding will also advance Freya’s multi-omics data science platform, which includes deep microbiome sequencing and vast multiplexed immune biomarker profiling in human clinical samples.